PubMed Health⌕ Search

Biomedical subjects

G Cornia

Publications and source records attributed to G Cornia.

At least 19 recordsLinked to original sources
PubMed1994

Calculating the economic impact of healthcare facilities on communities.

A methodology has been developed to calculate the direct, indirect, and induced spending effects of a healthcare facility on the community it serves. This methodology may be used by financial managers to produce data that demonstrate the effect of facilities on local economies. The data may be used by administrators to increase awareness of the pivotal economic role healthcare facilities play in communities among business and government leaders, economic development organizations, medical staff members, facility employees, trustees, and patients.

Accounting↗
PubMed1994

The role of community hospitals in the performance of local economies.

Many hospital administrators recognize an increasing need to educate the public on the important role their institutions play in the economic viability of the local community. Reasons include negative coverage by the press of increasing hospital costs, eroding philanthropy, managed care programs mandating out-of-area preferred providers, and declining city revenues, which have caused some municipalities to attempt to place not-for-profit health care facilities on the tax roles. This article reviews a technique that can be used by hospitals to build community support by demonstrating the favorable economic impact hospitals have on the communities they serve.

Commerce↗
PubMed1982

Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity.

Hypersecretion of immunoreactive gastric inhibitory polypeptide (IRGIP) has been reported previously in patients with diabetes mellitus (DM) and obesity. To ascertain the relative contribution of glucose intolerance and obesity to the abnormalities of IRGIP secretion, 114 subjects were studied during a standard oral glucose (75 g) tolerance test; responses of glucose, insulin, C-peptide, IRGIP, and glucagon were evaluated. The subjects were divided into six subgroups according to body weight and the degree of glucose intolerance. In normal weight subjects, the IRGIP response to oral glucose was significantly higher in the patients with impaired glucose tolerance (IGT) and DM than in the healthy control subjects (P less than 0.05). In the obese subjects, no significant differences in mean IRGIP responses could be detected among control, IGT, and DM subjects. In spite of similar IRGIP responses, the obese IGT patients did release more insulin than the obese control subjects, suggesting that incretin factors other than GIP may be operative in this condition. When obese and nonobese patients were compared, the obese subjects with normal glucose tolerance released a greater amount of IRGIP and insulin than the normal weight controls, whereas no significant difference between obese and nonobese could be found within the IGT and DM groups. We conclude that in the absence of obesity, glucose intolerance may induce IRGIP hypersecretion. On the other hand, obesity is associated with IRGIP hypersecretion, and glucose intolerance has no further effect, indicating a different pathogenetic mechanism for the IRGIP abnormalities. In both the obese and nonobese diabetic groups, IRGIP hypersecretion was associated with a failure of plasma glucagon levels to fall after oral glucose; this effect might be related to the glucagonotropic action of this peptide.

Adult↗
PubMed1976

[The place of citicolin in pulmonological therapy (author's transl)].

Citicolin, a psychodrug, is usually used for the treatment of ischemic cerebropathies. Its introduction into pulmonological therapy is suggested because Citicolin has the following properties: 1. Prevention of "acute respiratory distress syndrome" in neonates. 2. Improvement of chronic respiratory insufficiency. 3. Prevention of postoperative hypoventilation syndrome. 4. Improvment of respiratoy mechanics in syndromes with hyperelasticity of the lungs. 5. Recovery of permeability of the alveolo-capillary barrier for gases. 6. Compensation of the loss of surface-active substances after endobronchial aspiration of intubated patients.

Animals↗
PubMed1975

[Position of cyticholine in pneumologic therapy].

The position of cyticholine in lung lipid metabolism and hence in pneumological therapy (the subject of a personal hypothesis) is discussed. A summary is given of personal experimental work and papers read at the 1974 Padua meeting (11th December) held by the Societas Europae Physiologiae Clinicae Respiratoriae. It is shown that cyticholine may: 1) prevent the onset of acute neonatal respiratory distress; 2) improve chronic pneumogenous respiratory insufficiency; 3) prevent postoperative hypoventilation; 4) improve ventilation mechanics in hyperelastic lung syndromes; 5) increase the gas permeability of the air-blood barrier; 6) counterbalance the loss of surfactants caused by endobronchial aspiration in patients with tracheal tubes.

Choline↗
PubMed1975

[Use of 48/80 in the diagnosis and therapy of allergic asthma].

A review of the relevant literature is followed by the presentation of experimental and clinical results obtained with intradermal administration of the histamine releaser 48/80. The value of this substance in the diagnosis and treatment of bronchial asthma is stressed.

Asthma↗
PubMed1975

[Pulmonary surfactants].

Reference is made to classic studies pointing to the existence of lung surfactants in the alveolar lining layer and more recent investigations of their chemical nature. Attention is also given to work on biochemical and lung elasticity modifications caused by the employment of various drugs.

Animals↗